Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation

Biochemical Pharmacology 2026

View at publisher
Authors: Zehua He, Zhaoshuai Chen, Lei Wang, Ziyi Hu, Zhixin Wang, Jiehang Zhou, Yiran Zhu, Zhaorui Lyu, Wencan Zhang, Fan Lin, Xu Cao, Liqiong Xue
DOI: 10.1016/j.bcp.2026.117682
Cited by: 1
References: 53

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways Ferroptosis and cancer prognosis

Publication details

Journal / source
Biochemical Pharmacology
Publisher
Elsevier BV
Volume
245
Pages
117682–117682
Publication date
7 January 2026
Language
EN